| Dr Chandra M Graham-parker, MD | |
|
7309 Hanover Pkwy, Suite A&b, Greenbelt, MD 20770-2032 | |
| (301) 982-0657 | |
| (301) 982-5325 |
| Full Name | Dr Chandra M Graham-parker |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 7309 Hanover Pkwy, Greenbelt, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720018831 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D0060205 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1578638425 PECOS PAC ID: 3779495858 Enrollment ID: O20040805001280 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1073678637 PECOS PAC ID: 3779495858 Enrollment ID: O20100729000796 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1497023188 PECOS PAC ID: 3779495858 Enrollment ID: O20131029000108 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chandra M Graham-parker, MD 7309 Hanover Pkwy, Suite A&b, Greenbelt, MD 20770-2032 Ph: (301) 982-0657 | Dr Chandra M Graham-parker, MD 7309 Hanover Pkwy, Suite A&b, Greenbelt, MD 20770-2032 Ph: (301) 982-0657 |
News Archive
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
British researchers say that dull, steady, boring and unexciting jobs are no good for the heart.
› Verified 1 days ago
Dr. Siamack Bahrami, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 8957-k Edmonston Rd, Suite K, Greenbelt, MD 20770 Phone: 301-982-9333 Fax: 301-441-3672 | |
Danielle R Waldrop, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7525 Greenway Center Dr, #216, Greenbelt, MD 20770 Phone: 301-486-1870 | |
Ashley Elizabeth Pimperl, CRNP Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 7501 Greenway Center Dr Ste 410, Greenbelt, MD 20770 Phone: 240-616-3934 | |
Dr. Lenore Marie Tietjens-grillo, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 9001 Edmonston Rd Ste 40, Greenbelt, MD 20770 Phone: 240-790-3325 Fax: 301-345-1865 | |
Dr. Paul Dean Rogers, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 7309 Hanover Pkwy, Suite A&b, Greenbelt, MD 20770 Phone: 301-982-0657 | |
Dr. John Herbert Niles Jr., M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7500 Greenway Center Dr, Suite 620, Greenbelt, MD 20770 Phone: 301-474-5400 Fax: 301-474-0800 | |
Dr. Javaka K Moore, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7525 Greenway Center Drive, Suite 216, Greenbelt, MD 20770 Phone: 301-486-1870 Fax: 301-669-1873 |